A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER-Negative, Locally Advanced or Metastatic Breast Cancer

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05306340

Study #:
STUDY00149033

Start Date:
Mar 08, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05306340

View Complete Trial Details & Eligibility at ClinicalTrials.gov